Is ruxolitinib a potentially useful drug in hematological malignancies with RAS pathway hyperactivation?

Haematologica 2016 12;101(12):e492

Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Austria.

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2016.156448DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5479601PMC
December 2016
18 Reads

Publication Analysis

Top Keywords

ras pathway
4
pathway hyperactivation?
4
malignancies ras
4
hematological malignancies
4
ruxolitinib drug
4
drug hematological
4
hyperactivation?
1
ruxolitinib
1
hematological
1
pathway
1
malignancies
1
ras
1

Similar Publications